Thursday, April 12, 2018

Method Development and Validation for Assays Supporting Testing of Biologics (San Francisco, CA – June 21-22, 2018) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Method
Development and Validation for Assays Supporting Testing of Biologics”

conference has been added to ResearchAndMarkets.com’s
offering.

Biologics continue to be a steadily growing component of the
pharmaceutical industry. The advent of large molecule therapeutics
requires a different perspective on the assays needed to support
development through preclinical and clinical testing.

This 2-day seminar is designed to offer a broad overview of developing
and validating a range of assay methodologies for biologics with
specific key analysis of cell culture, assay variability, and DOE.
Specifically, this seminar covers essential concepts related to
cell-based potency methods, ELISA, and other methods supporting
biologics. In addition to potency methods this seminar addresses
immunogenicity methods for preclinical and clinical studies. The format
of the seminar offers an examination of current best practices as well
as time to dissect examples of documentation with emphasis on beneficial
systems to consider. Scientists who attend this 2-day seminar will gain
knowledge that will be beneficial in helping to achieve well-controlled
validated methods.

Learning Objectives:

  • Understanding the different requirements for small versus large
    molecules
  • Mapping appropriate timelines with decision points
  • Designing, developing, optimizing, and validating key methods
  • Potency methods, other release and stability methods
  • Preclinical and clinical methods
  • Use of DOE and statistical analysis
  • Handling of critical materials
  • Process monitoring concepts
  • Assessment of orthogonal methods
  • Assessing readiness for validation
  • Defining the validation protocol with real-time capture of data
    analysis
  • Maintaining quality through documentation

Who Should Attend:

Below titles working in biopharmaceuticals, pharmaceuticals, natural
products/botanicals will be benefited by attending this seminar:

  • Validation Scientists
  • QA/QC
  • Regulatory Affairs
  • Laboratory Managers
  • Assay Development Specialists
  • Statistician
  • CMC Titles
  • Bio Assay

For more information about this conference visit https://ift.tt/2vcczBc

Source link

Box Strengthens Product Offering With Major Product Updates – April 12, 2018

Box, Inc. (BOX – Free Report) introduced Admin Insights Dashboard, a major update to Box admin experience. The latest feature will enhance visibility, productivity and simplify processes.

Along with this, Box also unveiled advanced retention policies related to metadata in Box Governance.

The latest move will help Box to further strengthen its product portfolio. The advanced features are likely to boost the client base of the company which will drive the top-line growth.

Coming to the price performance, shares of Box have returned 19.5% over a year, underperforming the industry’s rally of 35.2%.

 

More on the headlines

Admin Insights Dashboard ensures data protection by providing flexibility, scalability, control and security insights. The latest dashboard helps in tracking usage of Box like upload, download, preview, login and edit, across the world. Also, admins can study the user behavior and implement it in personalized training sessions, which will drive the adoption rate of Box.

Extended power enterprise visibility ensures business efficiency and team productivity which is highly in demand.

Moreover, the new retention policies will allow businesses to transform their governance strategy by easily retaining content and unstructured data in the cloud. It will also lower dependency on legacy enterprise content management systems.

Robust Product Portfolio — Key Growth Driver

Box has an innovative product portfolio which will continue to help the company in attracting more customers and clients to its platform and generate higher revenues.

Recently, Box announced first-of-its-kind data processing addendum which is a simple self-serve solution for global data privacy preparedness.

In January 2018, Box introduced Box GxP Validation, which allows validation and operation of GxP compliance standard to its pharmaceutical, biotechnology and medical device business clients.

Late last year, the company launched Box Transform which provides a Box Consultant to business clients to develop customized solutions from their business insights.

Moreover, the company’s strategic partnership with Google Cloud and Microsoft’s Azure is helping it to integrate its platform. This has added enhanced features such as artificial intelligence, machine learning and image recognition capabilities to Box’s cloud products and services.

Growing Cloud Market

Box is well positioned to take advantage of the emerging trend of shifting traditional business model to a cloud based model due to massive amount of data.

Moreover, Box’s strong focus toward innovation and product portfolio expansion will continue to reap benefits from the rising demand for cloud content management products.

Per a report from Markets and Markets, the global cloud enterprise content management market is expected to reach $34.42 billion in 2022 by growing at a CAGR of 28.6% between 2017 and 2022.

Last quarter, Box generated revenues of $136.7 million which was mostly attributed to growing add-on products and strong clientele.

Courtesy to the current cloud market scenario, we believe the company’s market share will continue to gain momentum by winning clients.

 

Zacks Rank & Stocks to Consider

Currently, Box carries a Zacks Rank #3 (Hold).

Investors interested in the broader technology sector can consider some better-ranked stocks like Paycom Software (PAYC – Free Report) , Twitter (TWTR – Free Report) and Veeva Systems (VEEV – Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Long-term earnings growth rate for Paycom Software, Twitter and Veeva Systems is currently pegged at 24.75% and 21.5% and 17%, respectively.

Today’s Stocks from Zacks’ Hottest Strategies

It’s hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 – 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we’re willing to share their latest stocks with you without cost or obligation.

See Them Free>>



Source link